October 26, 2023.

Atmo Biosciences today announced it is partnering with ps.healthcare to shape its data strategy, and create a roadmap of future applications using machine learning (ML) and artificial intelligence (AI).

October 19, 2023.

The Atmo Gas Capsule could be used to help understand and monitor duodeno-gastric reflux and provide insight into its connection to delayed gastric emptying, according to an investigation by researchers from Monash University and Western Sydney University.

October 3, 2023.

Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.

September 25, 2023.

Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can help diagnose functional gastrointestinal disorders (FGIDs), which affect almost 40 per cent of Australians¹.

August 25, 2023.

Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.

August 10, 2023.

Atmo Biosciences today announced it has commenced a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in patients with suspected motility disorders.

The study involves simultaneous ingestion of the Atmo Gas Capsule and predicate device SmartPill to demonstrate the ability of Atmo’s gas-sensing capsule to assess whole and regional gut transit. Clinicians evaluate regional gut transit to help diagnose motility disorders such as gastroparesis (delayed emptying from the stomach), and slow transit constipation (slow transit through the colon).

15 May, 2023.

A Western Sydney University (WSU) and Monash University comparative study has validated the Atmo Gas Capsule relative to the SmartPill when measuring gastric emptying time and colonic transit time in patients with gastroparesis and chronic constipation.

Dr Jerry Zhou, lecturer and clinical researcher at WSU School of Medicine, presented findings from the study in a poster presentation at Digestive Disease Week  (DDW), held May 6-9 in Chicago.

1 May, 2023.

Atmo Biosciences today announced the appointment of renowned gastroenterologist Professor Eamonn Quigley as Chair of its Medical Advisory Board (MAB).

Prof. Quigley is David M. Underwood Chair of Medicine in Digestive Disorders and Chief of Gastroenterology and Hepatology at Houston Methodist Hospital in Texas. He is internationally known for his research on gastrointestinal motility disorders, particularly irritable bowel syndrome (IBS) and its link to the gut microbiome. As Atmo MAB Chair, Prof. Quigley will provide leadership and guidance regarding Atmo’s clinical trials portfolio.

“I am thrilled to have someone of Professor Quigley’s standing join our MAB as Chair,” said Atmo Biosciences CEO Malcolm Hebblewhite. “Eamonn is an internationally respected leader in gastroenterology. His ongoing research and thought leadership in the areas of motility and Small Intestinal Bacterial Overgrowth (SIBO) will be invaluable as we seek to develop these two key areas of focus in the U.S. and beyond.”

17 April, 2023.

Atmo Biosciences is strengthening its U.S. focus with the appointment of experienced medical device executive Chris Bertrand to the Atmo Board and establishment of a San Diego, California office.

Atmo Biosciences has raised A$8 million in a fully subscribed Series B funding round.

The raise was led by Japanese multinational company Otsuka Pharmaceutical, an existing strategic shareholder that took up more than its pro rata entitlement.